ProCE Banner Activity

HPTN 083: HIV Infections in the Yr 1 Unblinded Period in MSM and TGW Receiving Injectable CAB for HIV PrEP

Slideset Download
Conference Coverage

Efficacy advantage of long-acting CAB over FTC/TDF for HIV PrEP persisted 1 year after unblinding, with 3 new cases of INSTI mutations observed.

Released: October 27, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare